Article

Calorie Restriction-like Effects of 30 Days of Resveratrol Supplementation on Energy Metabolism and Metabolic Profile in Obese Humans

Top Institute Food and Nutrition (TIFN), Wageningen, The Netherlands.
Cell metabolism (Impact Factor: 16.75). 11/2011; 14(5):612-22. DOI: 10.1016/j.cmet.2011.10.002
Source: PubMed

ABSTRACT Resveratrol is a natural compound that affects energy metabolism and mitochondrial function and serves as a calorie restriction mimetic, at least in animal models of obesity. Here, we treated 11 healthy, obese men with placebo and 150 mg/day resveratrol (resVida) in a randomized double-blind crossover study for 30 days. Resveratrol significantly reduced sleeping and resting metabolic rate. In muscle, resveratrol activated AMPK, increased SIRT1 and PGC-1α protein levels, increased citrate synthase activity without change in mitochondrial content, and improved muscle mitochondrial respiration on a fatty acid-derived substrate. Furthermore, resveratrol elevated intramyocellular lipid levels and decreased intrahepatic lipid content, circulating glucose, triglycerides, alanine-aminotransferase, and inflammation markers. Systolic blood pressure dropped and HOMA index improved after resveratrol. In the postprandial state, adipose tissue lipolysis and plasma fatty acid and glycerol decreased. In conclusion, we demonstrate that 30 days of resveratrol supplementation induces metabolic changes in obese humans, mimicking the effects of calorie restriction.

Download full-text

Full-text

Available from: Sander Kersten, Sep 05, 2015
1 Follower
 · 
240 Views
 · 
213 Downloads
  • Source
    • "A considerable amount of data has accumulated on treating humans with STACs (Hubbard & Sinclair, 2014). Resveratrol has had mixed efficacy, in that its insulin-sensitizing effects (Ghanim et al., 2011; Smoliga et al., 2011) and DR-like phenotypes have been observed in elderly and obese humans (Timmers et al., 2011), but not in nonobese subjects with normal glucose tolerance (Yoshino et al., 2012). This suggests that STACs may restore homeostasis preferentially in metabolically compromised individuals. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The workshop entitled 'Interventions to Slow Aging in Humans: Are We Ready?' was held in Erice, Italy, on October 8-13, 2013, to bring together leading experts in the biology and genetics of aging and obtain a consensus related to the discovery and development of safe interventions to slow aging and increase healthy lifespan in humans. There was consensus that there is sufficient evidence that aging interventions will delay and prevent disease onset for many chronic conditions of adult and old age. Essential pathways have been identified, and behavioral, dietary, and pharmacologic approaches have emerged. Although many gene targets and drugs were discussed and there was not complete consensus about all interventions, the participants selected a subset of the most promising strategies that could be tested in humans for their effects on healthspan. These were: (i) dietary interventions mimicking chronic dietary restriction (periodic fasting mimicking diets, protein restriction, etc.); (ii) drugs that inhibit the growth hormone/IGF-I axis; (iii) drugs that inhibit the mTOR-S6K pathway; or (iv) drugs that activate AMPK or specific sirtuins. These choices were based in part on consistent evidence for the pro-longevity effects and ability of these interventions to prevent or delay multiple age-related diseases and improve healthspan in simple model organisms and rodents and their potential to be safe and effective in extending human healthspan. The authors of this manuscript were speakers and discussants invited to the workshop. The following summary highlights the major points addressed and the conclusions of the meeting. © 2015 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
    Aging Cell 04/2015; 14(4). DOI:10.1111/acel.12338 · 5.71 Impact Factor
  • Source
    • "et al . , 2006 ; Barger et al . , 2008 ; Pearson et al . , 2008 ; Rivera et al . , 2009 ; Rocha et al . , 2009 ) . While the resveratrol effects are intensively studied in animal models only few clinical trials were conducted so far to study the effects of resveratrol supplementation in the con - text of human obesity and coronary artery disease ( Timmers et al . , 2011 ; Tome - Carneiro et al . , 2013b ) , yet there exists some controversy ( Poulsen et al . , 2013 ) and the effect of resveratrol on the expression of inflammatory cytokines , in particular IL - 6 , IL - 8 , and MCP - 1 in obesity remains to be further investigated . Therefore it was the aim of this study to investigate the effects of re"
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity is associated with an inflammatory status and linked with a number of pathophysiological complications among them cardiovascular disease, type 2 diabetes mellitus, or the metabolic syndrome. Resveratrol was proposed to improve obesity-related inflammatory problems, but the effect of resveratrol on cytokine expression in obesity is not completely understood. In this study, we used an in vitro model of human adipose tissue inflammation to examine the effects of resveratrol on the production of the inflammatory cytokines IL-6, IL-8, and MCP-1. We found that resveratrol reduced IL-6, IL-8, and MCP-1 levels in a concentration-dependent manner in adipocytes under inflammatory conditions. Further experiments showed that the action of resveratrol was mainly due to its NFkB inhibitory potential. Thus, our data support the concept that resveratrol can alleviate obesity-induced up-regulation of inflammatory cytokines providing a new insight towards novel treatment options in obesity.
    Frontiers in Pharmacology 04/2015; 6. DOI:10.3389/fphar.2015.00079 · 3.80 Impact Factor
  • Source
    • "During resveratrol treatment the muscles of the subjects exhibited increased levels of activated AMPK, SIRT1 and PGC-1α as well as decreased inflammation markers (Timmers et al., 2011). "
    [Show abstract] [Hide abstract]
    ABSTRACT: The impact of dietary factors on brain health and vulnerability to disease is increasingly appreciated. The results of epidemiological studies, and intervention trials in animal models suggest that diets rich in phytochemicals can enhance neuroplasticity and resistance to neurodegeneration. Here we describe how interactions of plants and animals during their co-evolution, and resulting reciprocal adaptations, have shaped the remarkable characteristics of phytochemicals and their effects on the physiology of animal cells in general, and neurons in particular. Survival advantages were conferred upon plants capable of producing noxious bitter-tasting chemicals, and on animals able to tolerate the phytochemicals and consume the plants as an energy source. The remarkably diverse array of phytochemicals present in modern fruits, vegetables spices, tea and coffee may have arisen, in part, from the acquisition of adaptive cellular stress responses and detoxification enzymes in animals that enabled them to consume plants containing potentially toxic chemicals. Interestingly, some of the same adaptive stress response mechanisms that protect neurons against noxious phytochemicals are also activated by dietary energy restriction and vigorous physical exertion, two environmental challenges that shaped brain evolution. In this perspective article, we describe some of the signaling pathways relevant to cellular energy metabolism that are modulated by 'neurohormetic phytochemicals' (potentially toxic chemicals produced by plants that have beneficial effects on animals when consumed in moderate amounts). We highlight the cellular bioenergetics-related sirtuin, adenosine monophosphate activated protein kinase (AMPK), mammalian target of rapamycin (mTOR) and insulin-like growth factor 1 (IGF-1) pathways. The inclusion of dietary neurohormetic phytochemicals in an overall program for brain health that also includes exercise and energy restriction may find applications in the prevention and treatment of a range of neurological disorders. Published by Elsevier Ltd.
    Neurochemistry International 04/2015; DOI:10.1016/j.neuint.2015.03.009 · 2.65 Impact Factor
Show more